The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin

Journal of Clinical Gastroenterology

Volumn 39, Issue 1 SUPPL., 2005, Pages

  Collantes, Rochelle S ^a   Younossi, Zobair M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Darbepoetin alfa; Epoetin alfa; Filgrastim; Hematologic side effects; Hepatitis C

Indexed keywords

GROWTH FACTOR; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN;

ANEMIA; BLEEDING; BLOOD TOXICITY; BREATHING DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; INFECTION; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA;

EID: 11144252779     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000142583.00102.45     Document Type: Review

References (26)

1. Fried MW, Shiffman ML, Reddy KF, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
2. Hadziyannis SJ, Sette H, Morgan TR, et al. Peg-interferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
3. Manns MP, McHutchinson JG, Gordon SC, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-965.
4. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C 2002: June 10-12, 2002. Hepatology. 2002;36(Suppl 1):3-20.
5. Patel K, McHutchinson JG. Optimal dosing and duration of antiviral therapy in chronic hepatitis C: the initial course of treatment. Cleve Clin J Med Suppl. 2004;71(Suppl 3):8-12.
6. McHutchinson JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1 patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
7. Davis GL, Wong JB, McHutchinson JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.
8. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(Suppl 1):237-244.
9. Sulkowski M. Managing the hematologic complications of interferon/ribavirin. In: Clinical Care Options for Hepatitis Annual Update. Milford, MA: IMedOptions, 2003:101-122.
10. Peg-intron/Rebetol package insert. Kenilworth NJ: Schering Corp, 2002.
11. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290-299.
12. Allon M, Kleinman K, Walczyk M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 2002;72:546-555.
13. Adamson JW. The relationship of erythropoietin and iron metabolism to red cell production in humans. Semin Oncol. 1994;21(Suppl 3):9-15.
14. Dieterich DT, Wasserman R, Brau N, et al. Once weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98:2491-2499.
15. Afdhal NH, Dietrich D, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind randomized controlled trial. Gastroenterology. 2004;126:1302-1311.
16. Bloomfield M, Jaresko G, Zarek J, et al. Guidelines for using darbepoetin alfa in patients with chemotherapy-induced anemia. Pharmacotherapy. 2003;23(Suppl):110-118.
17. Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003;97:1312-1320.
18. Younossi ZM, Ong JP, Collantes R, et al. Darbepoetin alfa (DA) for ribavirin-induced anemia in patients with chronic hepatitis C (CH-C) treated with pegylated interferon and ribavirin (PEG-FN/RBV): a preliminary analysis [Abstract]. Gastroenterology. 2004;126(Suppl 1): 83A.
19. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon alpha. Gastroenterology. 2002;123:141-151.
20. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatohgy. 2002;36:1273-1279.
21. Neupogen (Filgrastim) physician package insert dated April 2, 1998. Thousand Oaks, CA: Amgen Inc.
22. Neulasta (Pegfilgrastim) physician package insert. Thousand Oaks, CA: Amgen Inc.
23. Van Thiel DH, Faruki H, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology. 1995;42:907-912.
24. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia and thrombocytopenia. Cleve Clin J Med. 2004;71(Suppl 3):17-21.
25. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology. 1998;28:1424-1429.
26. Rustgi VK, Lee P, Finnegan S, et al. Safety and efficacy of recombinant human IL-11 (Oprelvekin) in combination with interferon/ribavirin in hepatitis C patients with thrombocytopenia. Hepatology. 2002; 36:361A.